Processa Pharmaceuticals (PCSA) Insider Baluch Buys 203 Shares

Khoso Baluch, an insider at Processa Pharmaceuticals, Inc. (NasdaqCM: PCSA), bought 203 shares on June 26, 2026. The stock was trading near $1.92 on Wednesday.

Insider Buying and Selling at Processa Pharmaceuticals, Inc.

On June 26, 2026, several insiders at Processa Pharmaceuticals engaged in stock transactions. Khoso Baluch, along with Neal James, Geraldine Pannu, and Yorke Justin, each purchased 203 shares. These transactions were not planned under a Rule 10b5-1 trading plan.

Other Institutional Activity in Processa Pharmaceuticals

CONNECTIVE CAPITAL MANAGEMENT, LLC opened a new position in Processa Pharmaceuticals, acquiring 70,736 shares valued at about $178,608. STONEPINE CAPITAL MANAGEMENT, LLC significantly increased its stake by 42,677 shares, now holding 55,000 shares worth approximately $138,875, marking a 346.3% increase. GEODE CAPITAL MANAGEMENT, LLC also added 9,585 shares, bringing its total to 24,908 shares valued at $62,768, a 62.6% increase. Meanwhile, UBS GROUP AG reduced its holdings by 10,109 shares, now holding 2,531 shares valued at $6,391, an 80.0% decrease.

Processa Pharmaceuticals, Inc. Stock Down 2.0%

Shares of Processa Pharmaceuticals (NasdaqCM: PCSA) traded near $1.92 on Wednesday. The company has a market cap of approximately $5.1 million. It has no meaningful forward P/E ratio as it isn't currently profitable. The stock's 52-week low is $1.76, with a high of $14.25. The 50-day moving average is $2.56, and the 200-day moving average is $4.23. The current ratio stands at 0.979, while the quick ratio is 0.854.

Analysts Set New Price Targets

On September 2, 2025, HC Wainwright & Co. maintained its buy rating for Processa Pharmaceuticals with a price target of $1.00. Previously, on June 30, 2025, they had set a target of $2.00. The consensus among analysts remains a buy, with an average target price reflecting optimism about the company's potential.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc., based in Vero Beach, Florida, is a clinical-stage biopharmaceutical company focused on developing cancer therapy drugs. They aim to improve the safety and efficacy of cancer treatments by modifying existing FDA-approved oncology drugs. Their pipeline includes drugs like NGC-Cap, in Phase 2 trials for various cancers, and NGC-Iri, in preclinical trials. The company also develops non-oncology treatments such as PCS499 and PCS12852. Founded in 2015, the company is led by CEO Mr. George K. Ng Esq., J.D., and employs 12 people.

Bottom Line

Khoso Baluch's recent purchase of Processa Pharmaceuticals shares reflects continued insider interest in the company. As a clinical-stage biopharma firm, Processa is focused on innovative cancer therapies, attracting attention from both insiders and analysts. The information from these insider transactions provides a glimpse into the company's potential, though investors should remember that such filings are backward-looking and may not represent current positions.